Comparison of one-year real-world outcomes between red (670 nm) subthreshold micropulse laser treatment and intravitreal aflibercept injection for treatment-naïve diabetic macular edema
Purpose: To evaluate the treatment outcomes of subthreshold micropulse laser (SMPL) with a wavelength of 670 nm (red) for treatment-naïve diabetic macular edema (DME). Methods: A retrospective observational study which included 42 eyes in 34 patients diagnosed with treatment-naïve DME was conducted....
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Photodiagnosis and Photodynamic Therapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1572100024004666 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832575524887592960 |
|---|---|
| author | Wataru Kikushima Yukiko Furuhata Taiyo Shijo Mizuki Matsumoto Yoichi Sakurada Daphne Viel Tsuru Kenji Kashiwagi |
| author_facet | Wataru Kikushima Yukiko Furuhata Taiyo Shijo Mizuki Matsumoto Yoichi Sakurada Daphne Viel Tsuru Kenji Kashiwagi |
| author_sort | Wataru Kikushima |
| collection | DOAJ |
| description | Purpose: To evaluate the treatment outcomes of subthreshold micropulse laser (SMPL) with a wavelength of 670 nm (red) for treatment-naïve diabetic macular edema (DME). Methods: A retrospective observational study which included 42 eyes in 34 patients diagnosed with treatment-naïve DME was conducted. Twenty-one eyes underwent red SMPL and the other 21 eyes underwent intravitreal injection of aflibercept (IVA) as initial treatment and were followed up for 12 months. Best-corrected visual acuity (BCVA), central retinal thickness (CRT) on optical coherence tomography (OCT), vessel density (VD), and foveal avascular zone area on OCT angiography (OCTA) were measured and compared between the two groups. Results: In the red SMPL group, the mean BCVA slightly improved from 0.29 ± 0.28 at baseline to 0.22 ± 0.29 at 12 months (p = 0.18), while the mean CRT significantly decreased from 472 ± 200 µm at baseline to 320 ± 136 µm at 12 months (p = 0.003). At 12 months from baseline, the mean change in BCVA and CRT were similar between the red SMPL and IVA groups (p = 0.79 and p = 0.31, respectively). No significant change was detected in OCTA parameters except for VD at the nasal section in the red SMPL group. Conclusion: Red SMPL for treatment-naïve DME maintained BCVA and significantly reduced CRT at 12 months. These treatment outcomes were equivalent to IVA in real-world settings, which tend to be inferior to clinical trials. |
| format | Article |
| id | doaj-art-762c9392b04a42638583af62274a0c66 |
| institution | Kabale University |
| issn | 1572-1000 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Photodiagnosis and Photodynamic Therapy |
| spelling | doaj-art-762c9392b04a42638583af62274a0c662025-02-01T04:11:41ZengElsevierPhotodiagnosis and Photodynamic Therapy1572-10002025-02-0151104430Comparison of one-year real-world outcomes between red (670 nm) subthreshold micropulse laser treatment and intravitreal aflibercept injection for treatment-naïve diabetic macular edemaWataru Kikushima0Yukiko Furuhata1Taiyo Shijo2Mizuki Matsumoto3Yoichi Sakurada4Daphne Viel Tsuru5Kenji Kashiwagi6Corresponding author.; Department of Ophthalmology, University of Yamanashi, Shimokato 1110, Chuo, Yamanashi Prefecture, JapanDepartment of Ophthalmology, University of Yamanashi, Shimokato 1110, Chuo, Yamanashi Prefecture, JapanDepartment of Ophthalmology, University of Yamanashi, Shimokato 1110, Chuo, Yamanashi Prefecture, JapanDepartment of Ophthalmology, University of Yamanashi, Shimokato 1110, Chuo, Yamanashi Prefecture, JapanDepartment of Ophthalmology, University of Yamanashi, Shimokato 1110, Chuo, Yamanashi Prefecture, JapanDepartment of Ophthalmology, University of Yamanashi, Shimokato 1110, Chuo, Yamanashi Prefecture, JapanDepartment of Ophthalmology, University of Yamanashi, Shimokato 1110, Chuo, Yamanashi Prefecture, JapanPurpose: To evaluate the treatment outcomes of subthreshold micropulse laser (SMPL) with a wavelength of 670 nm (red) for treatment-naïve diabetic macular edema (DME). Methods: A retrospective observational study which included 42 eyes in 34 patients diagnosed with treatment-naïve DME was conducted. Twenty-one eyes underwent red SMPL and the other 21 eyes underwent intravitreal injection of aflibercept (IVA) as initial treatment and were followed up for 12 months. Best-corrected visual acuity (BCVA), central retinal thickness (CRT) on optical coherence tomography (OCT), vessel density (VD), and foveal avascular zone area on OCT angiography (OCTA) were measured and compared between the two groups. Results: In the red SMPL group, the mean BCVA slightly improved from 0.29 ± 0.28 at baseline to 0.22 ± 0.29 at 12 months (p = 0.18), while the mean CRT significantly decreased from 472 ± 200 µm at baseline to 320 ± 136 µm at 12 months (p = 0.003). At 12 months from baseline, the mean change in BCVA and CRT were similar between the red SMPL and IVA groups (p = 0.79 and p = 0.31, respectively). No significant change was detected in OCTA parameters except for VD at the nasal section in the red SMPL group. Conclusion: Red SMPL for treatment-naïve DME maintained BCVA and significantly reduced CRT at 12 months. These treatment outcomes were equivalent to IVA in real-world settings, which tend to be inferior to clinical trials.http://www.sciencedirect.com/science/article/pii/S1572100024004666Treatment-naïve DMERed SMPLAnti-VEGF agentaflibercept, OCTA |
| spellingShingle | Wataru Kikushima Yukiko Furuhata Taiyo Shijo Mizuki Matsumoto Yoichi Sakurada Daphne Viel Tsuru Kenji Kashiwagi Comparison of one-year real-world outcomes between red (670 nm) subthreshold micropulse laser treatment and intravitreal aflibercept injection for treatment-naïve diabetic macular edema Photodiagnosis and Photodynamic Therapy Treatment-naïve DME Red SMPL Anti-VEGF agent aflibercept, OCTA |
| title | Comparison of one-year real-world outcomes between red (670 nm) subthreshold micropulse laser treatment and intravitreal aflibercept injection for treatment-naïve diabetic macular edema |
| title_full | Comparison of one-year real-world outcomes between red (670 nm) subthreshold micropulse laser treatment and intravitreal aflibercept injection for treatment-naïve diabetic macular edema |
| title_fullStr | Comparison of one-year real-world outcomes between red (670 nm) subthreshold micropulse laser treatment and intravitreal aflibercept injection for treatment-naïve diabetic macular edema |
| title_full_unstemmed | Comparison of one-year real-world outcomes between red (670 nm) subthreshold micropulse laser treatment and intravitreal aflibercept injection for treatment-naïve diabetic macular edema |
| title_short | Comparison of one-year real-world outcomes between red (670 nm) subthreshold micropulse laser treatment and intravitreal aflibercept injection for treatment-naïve diabetic macular edema |
| title_sort | comparison of one year real world outcomes between red 670 nm subthreshold micropulse laser treatment and intravitreal aflibercept injection for treatment naive diabetic macular edema |
| topic | Treatment-naïve DME Red SMPL Anti-VEGF agent aflibercept, OCTA |
| url | http://www.sciencedirect.com/science/article/pii/S1572100024004666 |
| work_keys_str_mv | AT watarukikushima comparisonofoneyearrealworldoutcomesbetweenred670nmsubthresholdmicropulselasertreatmentandintravitrealafliberceptinjectionfortreatmentnaivediabeticmacularedema AT yukikofuruhata comparisonofoneyearrealworldoutcomesbetweenred670nmsubthresholdmicropulselasertreatmentandintravitrealafliberceptinjectionfortreatmentnaivediabeticmacularedema AT taiyoshijo comparisonofoneyearrealworldoutcomesbetweenred670nmsubthresholdmicropulselasertreatmentandintravitrealafliberceptinjectionfortreatmentnaivediabeticmacularedema AT mizukimatsumoto comparisonofoneyearrealworldoutcomesbetweenred670nmsubthresholdmicropulselasertreatmentandintravitrealafliberceptinjectionfortreatmentnaivediabeticmacularedema AT yoichisakurada comparisonofoneyearrealworldoutcomesbetweenred670nmsubthresholdmicropulselasertreatmentandintravitrealafliberceptinjectionfortreatmentnaivediabeticmacularedema AT daphnevieltsuru comparisonofoneyearrealworldoutcomesbetweenred670nmsubthresholdmicropulselasertreatmentandintravitrealafliberceptinjectionfortreatmentnaivediabeticmacularedema AT kenjikashiwagi comparisonofoneyearrealworldoutcomesbetweenred670nmsubthresholdmicropulselasertreatmentandintravitrealafliberceptinjectionfortreatmentnaivediabeticmacularedema |